Health Research

Lymphoma: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies

Basic Study Information

Will the new study drug, eFT508, be useful as a cancer treatment in the future?
This research study has two parts. Part 1 will test the safety and tolerability of the study drug at different doses and using different ways of taking the drug (powder mixed with a liquid diluent [suspension] taken once per day or capsules taken once or twice per day) to determine the recommended dose. Part 2 will test what effects the study drug has on the cancer and the safety of the study drug when given at the recommended dose.
Cancer Center

Lead Researcher (Principal Investigator)

Paul Barr

Study Contact Information

Yelena Lerman
(585) 276-8333

Additional Study Information

More Information

About this Study


Learn More About These Conditions